New dosing strategies for antibacterial agents in the neonate

被引:73
作者
de Hoog, M
Mouton, JW
van den Anker, JN
机构
[1] Sophia Childrens Univ Hosp, Erasmus MC Sophia, Dept Pediat, NL-3015 GJ Rotterdam, Netherlands
[2] Sophia Childrens Univ Hosp, Erasmus MC Sophia, Dept Med Microbiol & Infect Dis, NL-3015 GJ Rotterdam, Netherlands
[3] Canisius Wilhelmina Hosp, Dept Med Microbiol & Infect Dis, Nijmegen, Netherlands
[4] George Washington Univ, Sch Med & Hlth Sci, Dept Pediat, Washington, DC 20010 USA
[5] George Washington Univ, Sch Med & Hlth Sci, Dept Physiol & Pharmacol, Washington, DC 20010 USA
[6] Childrens Natl Med Ctr, Div Pediat Clin Pharmacol, Washington, DC 20010 USA
[7] Washington Pediat Pharmacol Res Unit, Washington, DC USA
关键词
antibiotics; meningitis; necrotizing enterocolitis; neonate; pharmacodynamics; review;
D O I
10.1016/j.siny.2004.10.004
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Dosing of 'antibiotics in neonates requires finding a delicate balance between maximal efficacy and minimal toxicity. There is a lack of data on efficacy of currently used antibiotics in neonates, and rational dosing therefore needs to be based on gestational- and postnatal-age-dependent pharmacokinetics in combination with surrogate markers. These surrogate markers are: (i) the area-under-the serum concentration time curve to minimum inhibitory concentration ratio (AUC/ MIC); (ii) peak concentration to MIC ratio (Cmax/MIC); and (iii) the time the concentration remains above the MIC (T > MIC). Whereas the efficacy of P-lactam antibiotics (including carbapenems) depends on T > MIC, the efficacy of most other antimicrobials (including aminoglycosides and fluoroquinolones) is related to AUC/ MIC and Cmax/MIC. Most modern dosing regimens are adequate when these concentration effect relationships are taken into account. Dosing adjustments in neonates are suggested, based on these relationships. Several antimicrobial combinations for treatment of meningitis and necrotizing enterocolitis exist. Empiric treatment should be based on efficacy, concerns about resistance as well as information from institutional microbiological surveillance. (c) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:185 / 194
页数:10
相关论文
共 77 条
[71]   ONCE-DAILY VERSUS TWICE-DAILY ADMINISTRATION OF CEFTAZIDIME IN THE PRETERM INFANT [J].
VANDENANKER, JN ;
SCHOEMAKER, RC ;
VANDERHEIJDEN, BJ ;
BROERSE, HM ;
NEIJENS, HJ ;
DEGROOT, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (09) :2048-2050
[72]   Ceftazidime pharmacokinetics in preterm infants: Effects of renal function and gestational age [J].
vandenAnker, JN ;
Schoemaker, RC ;
Hop, WCJ ;
vanderHeijden, BJ ;
Weber, A ;
Sauer, PJJ ;
Neijens, HJ ;
deGroot, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (06) :650-659
[73]  
VANDENANKER JN, 1995, BRIT J CLIN PHARMACO, V40, P439
[74]   Pharmacokinetics of intravenous flucloxacillin and amoxicillin in neonatal and infant cardiopulmonary bypass surgery [J].
Vargas, MRA ;
Danton, MH ;
Javaid, SM ;
Gray, J ;
Tobin, C ;
Brawn, WJ ;
Barron, DJ .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2004, 25 (02) :256-260
[75]   Clinical pharmacokinetics of teicoplanin [J].
Wilson, APR .
CLINICAL PHARMACOKINETICS, 2000, 39 (03) :167-183
[76]   PHARMACOKINETICS OF AMPICILLIN IN NEWBORN-INFANT [J].
YOSHIOKA, H ;
TAKIMOTO, M ;
RILEY, HD .
JOURNAL OF INFECTIOUS DISEASES, 1974, 129 (04) :461-464
[77]  
YOUNG TE, 2003, NEOFAX MANUAL DRUGS